A new gene therapy, a procurement process gone wrong, and backing away from a biosimilar…

Only 50 percent of clinical trial results in Europe are reported, but big pharma shares far less than half the blame.

The FDA’s Janet Woodcock explains how manufacturing will change in the coming years.

Recognizing and celebrating the efforts of both male and female scientists.

Eva decides to sort out her bioburden issues after a disturbing dream...

Nominations for The Medicine Maker’s annual Innovation Awards will close on Tuesday November 6.

Sitting Down With…Danny Bar-Zohar, Global Head of Neuroscience Development at Novartis, Switzerland

After many years of clinical trial failures in Alzheimer’s disease, pharma sees some positive results – although caution is recommended.

Does a medicine’s price consistently track with its benefits and value? Not in the US, according to a study.

A vaccine using mRNA demonstrates potential for broad influenza protection.